Clear Labels Act Weakens After Critical Provisions Removed Ahead of Senate Vote

# What changed and why it matters Act was introduced to make it possible for patients and clinicians to see where generic drugs were manufactured. The original bill included two provisions that safety advocates called central: requiring a unique facility identifier on labels (the FDA's code for a specific factory) and a rapid timeline for implementation. Both provisions were removed or delayed before the measure moved toward a full Senate vote.

# What the revised bill requires Under the updated language, manufacturers must put factory addresses on drug labels. That is the primary transparency change that remains. However, addresses can be inconsistent and hard to map to a single production site. A single address in some countries can cover multiple factories, or the same factory may be listed with slight address variations, making public traceability difficult.

# What was removed or delayed

• Unique facility identifier: The requirement to include the FDA-identifying facility number (previously tied to a DUNS-like identifier used in public tools) has been dropped. That identifier would have allowed researchers and the public to match drugs to specific inspection records for a factory.

Critics describe the changes as a weakening of the bill. Retired Army Col. Vic Suarez, who has advocated for more domestic pharmaceutical production, called the outcome a "clear watering down." Dr. Kevin Schulman, a Stanford professor researching generic drug economics, questioned why distributors and retailers need multiple years to adopt a label change.

Peter Baker, a former FDA inspector familiar with the affected companies, said the FDA could implement rules and guidance within a year and characterized a label change as straightforward. He and others said removing the facility identifier reduces the public's ability to trace drugs to factories with documented safety lapses.

# Practical effects for patients, clinicians, and researchers

• Patients and clinicians will get more location information than before, because labels should list factory addresses rather than only packager or distributor locations. But the information will be harder to use for direct accountability or research without a standardized facility code.
• Public tools that matched drugs to factory inspection histories relied on facility identifiers. Removing that field limits the ability of reporters, clinicians, and researchers to link specific drug lots to past inspection findings.

# Why traceability matters

# Where this leaves the legislation The bill retains a transparency element but with narrower, less actionable information and a much slower timeline for full implementation. Whether the change satisfies calls for greater accountability in the generic drug supply chain or simply creates a limited disclosure requirement will depend on post-passage rulemaking and whether future amendments restore more specific identifiers and faster timetables.